CClinicalTrials.gg
Not yet recruitingNCT06025175Updated Sep 6, 2023

Low Level Lazer Therapy Effect on Vertebral Artery Blood Flow in Elderly With Cervical Disc Degeneration

An interventional study of Low level Lazer therapy and Routine exercises in Disc Degeneration, sponsored by South Valley University. Not yet recruiting at 1 site in Egypt. Open to participants aged 60 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by South Valley University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years to 75 Years
Sex
All
01

Study summary

This study will include 60 elderly patients with cervical disc degeneration, from both gender who are aged from 60 - 75 years old.

Read the detailed description

The 60 patients will divided into two groups, with 30 patients in each group. group(A): will receive low level lazer and exercises for three times per week for 12 weeks.

Group (B): will receive only exercises. Resistivity index of both right and left vertebral arteries will be measured before and after the 12 weeks.

02

Conditions studied

  • Disc Degeneration
03

In context

Intervertebral Disc Degeneration

464 studies on the registry are indexed under Intervertebral Disc Degeneration; 98 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 261 interventional studies indexed under Intervertebral Disc Degeneration.

Browse Intervertebral Disc Degeneration studies →

Lead sponsor

South Valley University is the lead sponsor of 147 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. elderly patients with age range between 60 and 75 years old.
  2. with cervical disc degeneration.

Exclusion criteria

Exclusion Criteria:

  1. patients with uncontrolled hypertension.
  2. Patients with uncontrolled diabetes mellitus.
  3. Patients with severe cardiac or chest diseases.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Lazer group

    30 patients will receive low level lazer therapy 3 times per week for 12 weeks.

    Radiation: Low level Lazer therapy · Other: Routine exercises

  • Other
    Control group

    30 patients will receive only exercises.

    Other: Routine exercises

Interventions

  • RadiationLow level Lazer therapy

    30 patients will receive low level lazer therapy 3 times a week for 12 weeks.

  • OtherRoutine exercises

    30 patients will receive only routine exercises 3 times a week for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Resistivity index of both right and left vertebral arteries

    Resistivity index of both right and left vertebral arteries will be measured before and after the 12 weeks.

    Time frame: 12 weeks

07

Study locations

1 site
  • Shymaa yussuf abo zaid
    Qinā, Egypt
    • Shymaa Y Abo zaid, Doctoral · Contact · shaymaayoussef397@gmail.com · 01010941685
    • Shymaa Y Abo zaid, Doctoral · Contact · 01010941685
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06025175
Lead sponsor
South Valley University
Responsible party
Shymaa yussuf abo zaid (Lecturer, South Valley University) — Principal investigator
First posted
Sep 6, 2023
Start date
Sep 15, 2023 (estimated)
Primary completion
Oct 1, 2023 (estimated)
Completion
Jan 1, 2024 (estimated)
Last update
Sep 6, 2023

Study contacts

Shymaa Y Abo zaid
Contact
shaymaayoussef397@gmail.com
01010941685 ext. 01091631018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion